In this study, we tested the hypothesis that targeting microglial KCa3.1 channels could represent a therapeutic strategy to counteract GBM malignancy, helping microglia to re-acquire a more pro-inflammatory, antitumor phenotype. This evidence concerns the gene KCNN4 and glioblastoma.